These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 15241439)

  • 41. A revision of Billingham's tenets: the central role of lymphocyte migration in acute graft-versus-host disease.
    Sackstein R
    Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 1):2-8. PubMed ID: 16399577
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mini-Midi-Maxi? How to harness the graft-versus-myeloma effect and target molecular remission after allogeneic stem cell transplantation.
    Kröger N
    Leukemia; 2007 Sep; 21(9):1851-8. PubMed ID: 17568819
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Graft-versus-myeloma after donor leukocyte infusion: maintenance of marrow remission but extramedullary relapse with plasmacytomas.
    Zomas A; Stefanoudaki K; Fisfis M; Papadaki T; Mehta J
    Bone Marrow Transplant; 1998 Jun; 21(11):1163-5. PubMed ID: 9645583
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Second transplant from the same donor without conditioning for bone marrow aplasia after non-myeloablative hematopoietic stem cell transplantation for chronic myeloid leukemia].
    Ishikawa I; Miyamura K; Yamada M; Sasaki O; Harigae H; Kameoka J; Meguro K; Sasaki T
    Rinsho Ketsueki; 2005 Dec; 46(12):1288-92. PubMed ID: 16447801
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adoptive immunotherapy with donor lymphocyte infusions and interleukin-2 after high-dose therapy and autologous stem cell rescue for multiple myeloma.
    Ballester OF; Fang T; Raptis A; Ballester G; Wilcox P; Hiemenz J; Tan B
    Bone Marrow Transplant; 2004 Sep; 34(5):419-23. PubMed ID: 15286696
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
    Xia G; Truitt RL; Johnson BD
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor.
    Bellucci R; Alyea EP; Chiaretti S; Wu CJ; Zorn E; Weller E; Wu B; Canning C; Schlossman R; Munshi NC; Anderson KC; Ritz J
    Blood; 2005 May; 105(10):3945-50. PubMed ID: 15692072
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Adoptive immunotherapy with antigen-specific T cells in myeloma: a model of tumor-specific donor lymphocyte infusion.
    Kwak LW; Neelapu SS; Bishop MR
    Semin Oncol; 2004 Feb; 31(1):37-46. PubMed ID: 14970936
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cellular therapy: donor lymphocyte infusion.
    Peggs KS; Mackinnon S
    Curr Opin Hematol; 2001 Nov; 8(6):349-54. PubMed ID: 11604574
    [TBL] [Abstract][Full Text] [Related]  

  • 50. What is the future of immunotherapy in multiple myeloma?
    Rasche L; Hudecek M; Einsele H
    Blood; 2020 Nov; 136(22):2491-2497. PubMed ID: 32735639
    [TBL] [Abstract][Full Text] [Related]  

  • 51. T-cell receptor therapy shows promise in multiple myeloma.
    Bagcchi S
    Lancet Oncol; 2015 Sep; 16(9):e429. PubMed ID: 26212871
    [No Abstract]   [Full Text] [Related]  

  • 52. More potent graft-versus-myeloma effect than graft-versus-renal cell cancer effect.
    Juliusson G; Karlsson K; Malm C
    Leuk Lymphoma; 2002 Nov; 43(11):2233-4. PubMed ID: 12533054
    [No Abstract]   [Full Text] [Related]  

  • 53. Late recurrence of autologous GvHD in a myeloma patient: a myth or diagnostic challenge?
    El-Jurdi N; Ueda M; Jia L; Lazarus H
    Bone Marrow Transplant; 2017 Jun; 52(6):910-912. PubMed ID: 28319078
    [No Abstract]   [Full Text] [Related]  

  • 54. The benefits of an alloresponse: graft-versus-tumor.
    Barrett J; Childs R
    J Hematother Stem Cell Res; 2000 Jun; 9(3):347-54. PubMed ID: 10894356
    [No Abstract]   [Full Text] [Related]  

  • 55. Acute hepatitis-like presentation of graft-versus-host disease following donor lymphocyte infusion.
    Busca A; Locatelli F; Barbui A; Ghisetti V; Lovisone E; Aliberti S; Falda M
    Acta Haematol; 2003; 110(1):48-50. PubMed ID: 12975560
    [No Abstract]   [Full Text] [Related]  

  • 56. Infusion of in vivo expanded cord blood lymphocytes: A new strategy to control residual disease?
    Lamure S; Delage J; Vincent L; Fegueux N; Zhao-Yang L; Cartron G; Ceballos P; De Vos J
    Curr Res Transl Med; 2018 Sep; 66(3):91-93. PubMed ID: 29525419
    [No Abstract]   [Full Text] [Related]  

  • 57. Dueling lymphocytes: picking the winner.
    Stein J; Mor E
    Transplantation; 2004 Dec; 78(12):1719-20. PubMed ID: 15614143
    [No Abstract]   [Full Text] [Related]  

  • 58. Graft-versus-myeloma effect.
    Aschan J; Lönnqvist B; Ringdén O; Kumlien G; Gahrton G
    Lancet; 1996 Aug; 348(9023):346. PubMed ID: 8709723
    [No Abstract]   [Full Text] [Related]  

  • 59. Multiple myeloma: infusions of low doses of donor lymphocytes are also effective in reversing disease recurrence after bone marrow transplantation.
    du Toit C; Novitzky N
    Br J Haematol; 1998 Dec; 103(4):1210-1. PubMed ID: 9886347
    [No Abstract]   [Full Text] [Related]  

  • 60. The next transplant frontier: treating solid tumors.
    Vastag B
    J Natl Cancer Inst; 2000 Aug; 92(16):1286. PubMed ID: 10944543
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.